CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE

被引：1
|
作者：
Mocciaro, F. [1 ]
Renna, S. [1 ]
Orlando, A. [1 ]
Olivo, M. [1 ]
Sinagra, E. [1 ]
Cottone, M. [1 ]
机构：
[1] Villa Sofia V Cervello Hosp, Dept Med, Palermo, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2011年 / 43卷
关键词：
D O I：
10.1016/S1590-8658(11)60353-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S189 / S189
页数：1
相关论文
共 50 条
  • [41] Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials
    Loftus, Edward V., Jr.
    Colombel, Jean-Frederic
    Schreiber, Stefan
    Randall, Charles W.
    Regueiro, Miguel
    Ali, Tauseef
    Arendt, Catherine
    Coarse, Jason
    Spearman, Marshall
    Kosutic, Gordana
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (12) : 1753 - 1762
  • [42] SAFETY UPDATE ON CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH LONG-TERM EXPOSURE
    Mariette, X.
    van Vollenhoven, Ronald F.
    Bykerk, V.
    de Longueville, M.
    Arendt, C.
    Luijtens, K.
    Cush, J.
    RHEUMATOLOGY, 2013, 52 : 86 - 86
  • [43] Certolizumab pegol as treatment for Crohn's disease in a community IBD practice
    Shafran, Ira
    Burgunder, Patricia
    Fakih, Faisal
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S27 - S27
  • [44] Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohn's Disease: 5-Year Results
    Ptak, Theadore
    Younes, Ziad
    Shafran, Ira
    Lee, Scott
    Miner, Philip B.
    Kayhan, Cem
    Kosutic, Gordana
    Coarse, Jason
    Hasan, Iram
    Spearman, Marshall
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S774 - S775
  • [45] Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use
    Danese, Silvio
    Mocciaro, Filippo
    Guidi, Luisa
    Scribano, Maria Lia
    Comberlato, Michele
    Annese, Vito
    Colombo, Elisabetta
    Stefanelli, Tommaso
    Marzo, Manuela
    Vangeli, Marcello
    Pulitano, Raffaella
    Manca, Aldo
    Armuzzi, Alessandro
    Malesci, Alberto
    Prantera, Cosimo
    Cottone, Mario
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (08) : 1168 - 1170
  • [46] Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results
    Schreiber, Stefan
    Hanauer, Stephen B.
    Feagan, Brian G.
    Bloomfield, Ralph
    Rutgeerts, Paul
    Sandborn, William J.
    GASTROENTEROLOGY, 2007, 132 (04) : A504 - A504
  • [47] Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
    Knyazev, O., V
    Kagramanova, A., V
    Lishchinskaya, A. A.
    Samsonova, N. G.
    Orlova, N., V
    Rogozina, V. A.
    Parfenov, A., I
    TERAPEVTICHESKII ARKHIV, 2018, 90 (06) : 74 - 80
  • [48] Certolizumab pegol (CDP870) for treatment of Crohn's disease
    Sisson, G
    Harris, A
    GASTROENTEROLOGY, 2006, 130 (01) : 285 - 286
  • [49] New biologics in the management of Crohn's disease: focus on certolizumab pegol
    Colombo, Elisabetta
    Bossa, Fabrizio
    Latiano, Anna
    Palmieri, Orazio
    Andriulli, Angelo
    Annese, Vito
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2009, 2 : 61 - 68
  • [50] Certolizumab pegol for maintenance of medically induced remission in Crohn's disease
    Okabayashi, Shinji
    Yamazaki, Hajime
    Yamamoto, Ryohei
    Anan, Keisuke
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Honzawa, Yusuke
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
12345